Optimizing Dvl PDZ domain inhibitor by exploring chemical space

Journal of Computer-Aided Molecular Design

Volumn 23, Issue 1, 2009, Pages 37-47

  Shan, Jufang ^a,b   Zheng, Jie J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Chemical space; NMR; PDZ domain inhibitors; SAR; Virtual screening; Wnt signaling pathway

Indexed keywords

LEAD COMPOUNDS;

CHEMICAL SPACE; HIGH THROUGHPUT SCREENING; LEAD OPTIMIZATION; PDZ DOMAIN INHIBITOR; PDZ DOMAINS; SCREENING TECHNOLOGY; STRUCTURE-ACTIVITY RELATIONSHIPS; TECHNOLOGY IDENTIFICATION; VIRTUAL SCREENING; WNT SIGNALING PATHWAYS;

NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

DISHEVELLED PROTEIN; NSC 668036; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DATA BASE; HIGH THROUGHPUT SCREENING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 58049192960     PISSN: 0920654X     EISSN: 15734951     Source Type: Journal    
DOI: 10.1007/s10822-008-9236-1     Document Type: Article

References (28)

1. Burbaum J, Sigal N (1997) Curr Opin Chem Biol 1:72. doi: 10.1016/ S1367-5931(97)80111-1
2. Liu B, Li S, Hu J (2004) Am J Pharmacogenomics 4:263. doi: 10.2165/ 00129785-200404040-00006
3. Bleicher K, Böhm H, Müller K, Alanine A (2003) Nat Rev Drug Discov 2:369. doi: 10.1038/nrd1086
4. Keseru G, Makara G (2006) Drug Discov Today 11:741. doi: 10.1016/ j.drudis.2006.06.016
5. Irwin J, Shoichet B (2005) J Chem Inf Model 45:177. doi: 10.1021/ ci049714+
6. Hann M, Oprea T (2004) Curr Opin Chem Biol 8:255. doi: 10.1016/ j.cbpa.2004.04.003
7. Shan J, Shi D, Wang J, Zheng J (2005) Biochemistry 44:15495. doi: 10.1021/bi0512602
8. Dev K (2004) Nat Rev Drug Discov 3:1047. doi: 10.1038/nrd1578
9. Fry D, Vassilev L (2005) J Mol Med 83:955. doi: 10.1007/s00109-005-0705-x
10. Fujii N, Haresco J, Novak K, Stokoe D, Kuntz I, Guy R (2003) J Am Chem Soc 125:12074. doi: 10.1021/ja035540l
11. Fujii N, You L, Xu Z, Uematsu K, Shan J, He B et al (2007) Cancer Res 67:573. doi: 10.1158/0008-5472.CAN-06-2726
12. Joshi M, Vargas C, Boisguerin P, Diehl A, Krause G, Schmieder P et al (2006) Angew Chem Int Ed Engl 45:3790. doi: 10.1002/anie.200503965
13. Barker N, Clevers H (2006) Nat Rev Drug Discov 5:997. doi: 10.1038/ nrd2154
14. Wolber G, Langer T (2005) J Chem Inf Model 45:160. doi: 10.1021/ci049885e
15. Cheyette B, Waxman J, Miller J, Takemaru K, Sheldahl L, Khlebtsova N et al (2002) Dev Cell 2:449. doi: 10.1016/S1534-5807(02)00140-5
16. Kramer B, Rarey M, Lengauer T (1999) Proteins 37:228. doi:10.1002/ (SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8
17. Friesner R, Banks J, Murphy R, Halgren T, Klicic J, Mainz D et al (2004) J Med Chem 47:1739. doi: 10.1021/jm0306430
18. London T, Lee H, Shao Y, Zheng J (2004) Biochem Biophys Res Commun 322:326. doi: 10.1016/j.bbrc.2004.07.113
19. Wong H, Bourdelas A, Krauss A, Lee H, Shao Y, Wu D et al (2003) Mol Cell 12:1251. doi: 10.1016/S1097-2765(03)00427-1
20. Delaglio F, Grzesiek S, Vuister G, Zhu G, Pfeifer J, Bax A (1995) J Biomol NMR 6:277. doi: 10.1007/BF00197809
21. Goddard TD, Kneller DG, SPARKY 3. University of California, San Francisco. http://www.cgl.ucsf.edu/home/sparky/
22. Worrall J, Reinle W, Bernhardt R, Ubbink M (2003) Biochemistry 42:7068. doi: 10.1021/bi0342968
23. Gund P (1977) Prog Mol Subcell Biol 5:17
24. Guner OF (2000) Pharmacophore perception, development, and use in drug design. International University Line, La Jolla
25. Langer T, Hoffmann RD (2006) Pharmacophores and pharmacophore searches. Wiley-VCH, Weinheim
26. Zerbe O (2003) BioNMR in drug research (methods and principles in medicinal chemistry), vol 16. Wiley-VCH, Weinheim
27. Hammond M, Harris B, Lim W, Bartlett P (2006) Chem Biol 13:1247. doi: 10.1016/j.chembiol.2006.11.010
28. Wallace A, Laskowski R, Thornton J (1995) Protein Eng 8:127. doi: 10.1093/protein/8.2.127